Merkel Cell Carcinoma Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Merkel cell Carcinoma also known as neuroendocrine carcinoma of the skin is a rare malignant cancer which appears as bluish or red colored nodule generally on face, neck or head. Merkel cells are present at the base of epidermis (outermost layer of skin) and are responsible for the sense of touch. It is an aggressive form of cancer which tends to metastasize quickly. The exact cause of the cancer is still not known, however, excessive exposure to sunlight and a weakened immune system may increase the risk of getting this cancer.
The report provides Merkel cell carcinoma treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Amgen Inc, Millennium Pharmaceuticals Inc, Apcure SAS, BeiGene Ltd, Bristol-Myers Squibb Co, Checkpoint Therapeutics Inc, Exelixis Inc, Immune Design Corp, NantKwest Inc, OncoSec Medical Inc, Philogen SpA, Tarveda Therapeutics Inc, Nektar Therapeutics among others.
By Molecule Type
By Route of Administration